A61K 47/6893
Clearing therapy or enhanced clearance, i.e. using an antibody clearing agents in
Official title: {clearing therapy or enhanced clearance, i.e. using an antibody clearing agents in addition to T-A and D-M}
A61K47/6893 (Clearing therapy or enhanced clearance, i.e. using an antibody clearing agents in) appears on 60 US grants and 33 published applications in this corpus.
Search patents in A61K- Granted patents
- 60
- Published applications
- 33
- Assignees
- 23
- Inventors
- 90
- Latest grant
- 25 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 2 | 0 |
| 1995 | 0 | 0 |
| 1996 | 3 | 0 |
| 1997 | 8 | 0 |
| 1998 | 1 | 0 |
| 1999 | 7 | 0 |
| 2000 | 2 | 0 |
| 2001 | 5 | 0 |
| 2002 | 3 | 4 |
| 2003 | 2 | 6 |
| 2004 | 3 | 2 |
| 2005 | 2 | 0 |
| 2006 | 4 | 2 |
| 2007 | 4 | 1 |
| 2008 | 0 | 1 |
| 2009 | 2 | 0 |
| 2010 | 0 | 1 |
| 2011 | 2 | 0 |
| 2012 | 1 | 1 |
| 2013 | 1 | 1 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 1 | 0 |
| 2017 | 0 | 1 |
| 2018 | 0 | 0 |
| 2019 | 1 | 3 |
| 2020 | 0 | 0 |
| 2021 | 0 | 1 |
| 2022 | 1 | 1 |
| 2023 | 0 | 3 |
| 2024 | 2 | 3 |
| 2025 | 0 | 0 |
| 2026 | 2 | 2 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- DOTA-hapten compositions for anti-DOTA/anti-tumor antigen bispecific antibody pretargeted radioimmunotherapy25 Aug 2026US 12,714,758 B2Memorial Sloan Kettering Cancer Center
- Compositions and methods for reducing off-target toxicity of antibody drug conjugates12 May 2026US 12,624,123 B2The Research Foundation for The State University of New York
- Pre-targeting strategies for molecular imaging and/or radioimmunotherapy9 Jul 2024US 12,029,798 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- Dimerization strategies and compounds for molecular imaging and/or radioimmunotherapy2 Jan 2024US 11,857,648 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- N-acetylgalactosamino dendron-clearing agent for dota-pretargeted radioimmunotherapy16 Aug 2022US 11,413,354 B2Memorial Sloan Kettering Cancer Center
- Vhh polypeptides that bind to light chain (lc) proteases of botulinum neurotoxins (bonts) and methods of use thereof2 Jul 2026US 2026/0184813 A1Trustees of Tufts College
- Anti-cd45-ign antibody drug conjugates and uses thereof16 Apr 2026US 2026/0102505 A1
- Pre-targeting strategies for molecular imaging and/or radioimmunotherapy10 Oct 2024US 2024/0335571 A1University of Pittsburgh—Of the Commonwealth System of Higher Education
- Dimerization strategies and compounds for molecular imaging and/or radioimmunotherapy12 Sep 2024US 2024/0299599 A1University of Pittsburgh—Of the Commonwealth System of Higher Education
- Nano-structural Protein Degradation Tool, Use, and Preparation Method thereof, and Lipid-based Protein Degradation Tool, Use, and Preparation Method thereof1 Feb 2024US 2024/0033374 A1Henan University
Most cited
By later US patents
- Targeted combination immunotherapy of cancer175US 6,077,499 AImmunomedics, Inc. · 2000
- Pretargeting methods and compounds125US 6,217,869 B1NeoRx Corporation · 2001
- Detection and therapy of lesions with biotin/avidin conjugates116US 5,525,338 AImmunomedics, Inc. · 1996
- Modified antibodies for enhanced hepatocyte clearance105US 4,859,449 ACenter for Molecular Medicine and Immunology · 1989
- Alteration of pharmacokinetics of proteins by charge modification103US 5,322,678 ANeoRx Corporation · 1994